Assessment of COVID-19 Incidence and Severity Among Recipients of Allogenic Stem Cell Transplant After 1 or 2 mRNA Booster Doses During the Omicron Wave in France-Reference-Cited by-同舟云学术

Assessment of COVID-19 Incidence and Severity Among Recipients of Allogenic Stem Cell Transplant After 1 or 2 mRNA Booster Doses During the Omicron Wave in France

Published:2022-12-19 Issue:12 Volume:5 Page:e2247534
ISSN:2574-3805
Container-title:JAMA Network Open
language:en
Short-container-title:JAMA Netw Open

Author:

Letailleur Valentin¹,Le Bourgeois Amandine¹,Guillaume Thierry¹²,Jullien Maxime¹,Coste-Burel Marianne³,Béné Marie C.²⁴,Chevallier Patrice¹²

Affiliation:

1. Hematology Department, Nantes University Hospital, Nantes, France

2. Institut National de la Santé et de la Recherche Médicale Unité Mixte de Recherche UMR1232, Centre de Recherche en Cancérologie et Immunologie Nantes-Angers, Institut de Recherche en Santé de l’Université de Nantes, University of Nantes, France

3. Virology Department, Nantes University Hospital, Nantes, France

4. Hematology Biology Department, Nantes University Hospital, Nantes, France

Abstract

This cohort study assesses the incidence and severity of COVID-19 among vaccinated recipients of allogenic stem cell transplant in a single center after 1 or 2 messenger RNA booster doses during the Omicron wave in France.

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jamanetworkopen/articlepdf/2799692/letailleur_2022_ld_220286_1670855983.16816.pdf

Reference6 articles.

1. Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: a Société Francophone de Greffe de Moelle et de Thérapie cellulaire (SFGM-TC) multicentre cohort study.;Xhaard;Br J Haematol,2021

2. A portrait of SARS-CoV-2 infection in patients undergoing hematopoietic cell transplantation: a systematic review of the literature.;Bailey;Curr Oncol,2022

3. Safety and antibody response after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant.;Le Bourgeois;JAMA Netw Open,2021

4. Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant.;Le Bourgeois;Br J Haematol,2022

5. Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients.;Chevallier;Hematol Oncol,2022

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Attenuated immunogenicity of SARS-CoV-2 vaccines and risk factors in stem cell transplant recipients: a meta-analysis;Blood Advances;2023-09-18